Bridgewater Associates LP Has $629,000 Stock Holdings in Haemonetics Co. (NYSE:HAE)

Bridgewater Associates LP decreased its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 82.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,826 shares of the medical instruments supplier's stock after selling 35,747 shares during the quarter. Bridgewater Associates LP's holdings in Haemonetics were worth $629,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of HAE. BNP Paribas Financial Markets raised its position in shares of Haemonetics by 174.5% during the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock worth $1,362,000 after purchasing an additional 10,774 shares during the period. FMR LLC increased its stake in Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock worth $62,257,000 after purchasing an additional 521,640 shares in the last quarter. Loomis Sayles & Co. L P raised its holdings in Haemonetics by 8.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier's stock worth $13,171,000 after buying an additional 12,310 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of Haemonetics by 10.9% in the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier's stock worth $66,206,000 after buying an additional 80,783 shares during the period. Finally, Cerity Partners LLC increased its position in shares of Haemonetics by 31.1% in the third quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier's stock worth $712,000 after acquiring an additional 2,102 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Stock Down 2.5 %

Shares of HAE stock traded down $2.22 on Tuesday, hitting $85.26. 365,206 shares of the stock were exchanged, compared to its average volume of 553,887. The firm has a market capitalization of $4.28 billion, a P/E ratio of 35.41, a price-to-earnings-growth ratio of 1.36 and a beta of 0.38. Haemonetics Co. has a fifty-two week low of $70.25 and a fifty-two week high of $97.97. The business has a 50-day moving average of $80.21 and a 200 day moving average of $82.00. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company had revenue of $345.50 million for the quarter, compared to analysts' expectations of $342.57 million. During the same period in the prior year, the firm earned $0.99 EPS. Haemonetics's quarterly revenue was up 8.6% compared to the same quarter last year. Equities analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on HAE shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $112.00 price objective on shares of Haemonetics in a research note on Tuesday. CL King initiated coverage on shares of Haemonetics in a research report on Friday, September 13th. They issued a "buy" rating and a $116.00 price target for the company. Bank of America began coverage on shares of Haemonetics in a report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price target on the stock. BTIG Research assumed coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They set a "buy" rating and a $112.00 price objective for the company. Finally, Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price target on the stock in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.